

15 Short Title: Modeling Lassa fever to inform vaccine trial design

Abstract

Background

- Lassa fever (LF) is an acute viral hemorrhagic disease endemic to West Africa that has been declared a
- priority disease by the World Health Organization due to its severity and the lack of a vaccine or
- effective treatment options. Several candidate vaccines are currently in development and are expected
- to be ready for phase III field efficacy trials soon. However, most LF cases and deaths are believed to go
- unreported, and as a result we lack a clear understanding of several aspects of LF epidemiology and
- immunology that are critical to the design of vaccine efficacy trials.
- *Methods*
- 25 To help guide vaccine trial design and site selection we estimated the force of infection (FOI) in all $1st$
- 26 and 2^{nd} administrative units in West Africa from published seroprevalence studies. We next estimated LF
- reporting probabilities using these FOI estimates and LF case and death reports and then projected FOI
- 28 in all admin1 and admin2 areas without seroprevalence data. We then extrapolated age-specific LF
- incidence rates from FOI estimates under different assumptions regarding the level of protection against
- reinfection among seropositive and seronegative individuals with a history of prior infection.

Results

Projected FOI estimates and modeled annual LF incidence rates indicate that Sierra Leone, southern

- Guinea, and a few areas within Nigeria would likely yield the highest LF case incidence rates during a
- vaccine trial. Estimated LF incidence rates were highly sensitive to assumptions about Lassa
- immunology, particularly the frequency of seroreversion among previously infected individuals and the
- extent to which seroreverted individuals retain protection against reinfection and more severe disease

outcomes.

Conclusions

with Lassa virus (LASV), an arenavirus that circulates in rodent populations but can spill over to human

57 populations.¹ Transmission is thought to occur through human contact with rodents either due to

- 58 infestation of human residences or processing for food.² Importantly, direct human-to-human
- transmission in nosocomial settings also occurs, creating a potential for wider spread of the virus to
- 60 naive populations.² Most LASV infections are presumed to be asymptomatic or result in mild disease,
- 61 but up to 20% can result in a severe, life-threatening hemorrhagic illness.² In these instances, case

62 fatality rates among clinical LF cases can reach 60%.¹ Previous studies have estimated that 100,000-63 300,000 LASV infections and 5,000 LF deaths occur annually in sub-Saharan Africa. However, these 64 estimates were extrapolated from limited serological studies conducted decades ago and may not 65 accurately reflect current conditions across West Africa.^{3,4} 66 Despite its severity and burden, there are currently few therapeutic options for LF and no licensed 67 vaccines.¹ In 2018, the World Health Organization (WHO) declared LF a 'Priority Disease,' and the 68 Coalition for Epidemic Preparedness Innovations (CEPI) subsequently invested in the development of six

69 LF vaccine candidates, four of which have entered clinical trials.¹¹ Individuals previously infected with

70 LASV maintain LASV-specific CD4+ memory T cells for years after the infection has cleared.⁶ This, along

71 with animal vaccination models, suggests that vaccination will provide meaningful protective immunity

72 against severe LF.¹² However, there are currently no immunological correlates of protection against LF

73 and the risk of severe disease rules out the option of controlled human infection studies to evaluate the

74 clinical benefit of a candidate vaccine.¹³ Instead, field efficacy trials are necessary to determine the

75 efficacy of vaccine candidates.

 Assuming a primary endpoint of PCR-positive symptomatic LF disease, CEPI has targeted a minimum annual LF incidence rate of 1% to ensure an adequately powered trial. An ideal study site will have a baseline seroprevalence that indicates the presence of frequent LASV spillover, but which is low enough that existing immunity in the population does not substantially reduce the LF incidence rate. Identifying populations in which these criteria are likely to be met is the most critical consideration in Lassa vaccine \cdot trial design.^{7,8} However, our understanding of Lassa epidemiology is limited by a lack of good prospective epidemiological data and inconsistent disease surveillance across West Africa. Since 2018, reported LF case counts have increased dramatically, although this is partly due to changes in surveillance and 84 diagnostics.⁵ Other than a couple of prospective community studies in Sierra Leone and Mali that tested 85 individuals for evidence of a recent LASV infection,^{3,7} and a few hospital-based surveillance studies of

86 severe LF cases, ^{8,9} most epidemiological data on Lassa come from national surveillance programs. A majority of LF cases are not detected by current clinical surveillance systems because common LF symptoms—such as fever, malaise, headache, and muscle pain—closely resemble those of other febrile 89 illnesses endemic to the region.^{1,2,11} In addition, the extent of national LF surveillance varies considerably from country to country in West Africa, complicating comparisons of incidence rates between different 91 LF-endemic areas. For example, Nigeria has expanded LF surveillance over the past decade, $5,12$ while changes in healthcare-seeking behaviors in areas of Sierra Leone heavily impacted by the 2013-2016 93 Ebola virus epidemic have led to declines in the detection of febrile illnesses, including LF.^{9,13} Because of the limited availability of epidemiological data for Lassa, in 2020 CEPI initiated a long-term, 95 multi-country, prospective epidemiological study of Lassa disease and infection in West Africa.¹⁴ This study, called Enable, is tracking over 20,000 participants across five West African countries with the goal of identifying baseline seroprevalence, LASV infection rates, LF incidence rates, serological dynamics, and individual and community-level risk factors for infection and disease. Due to the impact of the COVID-19 pandemic, data from the Enable study have not yet been published. However, preliminary findings from the study presented in an interim report suggest that LASV infection is common in several 101 of the study locations and that prior infection does not confer lifelong immunity.¹⁵ Epidemiological data such as those being collected in Enable are essential for understanding the current status of Lassa in the region. In the absence of detailed epidemiological data across the entire geographic range of LF, statistical models can be used to anticipate the future disease incidence for the purpose of vaccine trial planning. Such a modeling framework, based on existing epidemiological data and accounting for the factors that drive pathogen transmission and infection risk, can incorporate new epidemiological data from Enable and other studies as it becomes available. This framework can include ecological factors that influence the spatial and temporal patterns of disease and immunological factors related to immunity.

 LASV is thought to infect humans through exposure to the urine or feces of the multimammate rat, 111 Mastomys natalensis, which serves as the primary reservoir host.¹⁶ As a result, LASV spillover typically occurs seasonally in rural and peri-urban areas of West Africa where agricultural practices, 113 socioeconomic factors, and the built environment promote rodent-human interactions. $17-19$ Field studies have identified several risk factors associated with *M. natalensis* abundance in villages and individual houses, but have also found that *M. natalensis* abundance and LASV seropositivity in rodents are 116 spatially heterogeneous at multiple spatial scales, from the village- to the subnational-level.^{20–22} Moreover, incidence of disease can be markedly seasonal on broad spatial scales, suggesting important variation in either rodent infection rates or contact with humans. Overall, the substantial spatial and temporal variation in LASV prevalence is an important consideration for vaccine trial site selection, as potential trial locations might have different LF incidence rates despite their proximity and similar environmental conditions. Because of the scarcity of longitudinal data, it is difficult to assess LF incidence, the duration of immunity following infection, or reinfection rates. Two longitudinal serology studies have found evidence that 3- 6% of seropositive individuals seroreverted from IgG+ to IgG- between sampling periods, suggesting that 125 infection-induced immunity may not be permanent.^{23,24} Preliminary data from CEPI's Enable study also 126 indicate that seroreversion occurs relatively frequently.¹⁴ A further complication for our understanding of LASV infection rates is that the frequency of severe LF following infection is uncertain. It is typically stated that 80% of Lassa fever infections are asymptomatic, but data supporting this assumption is 129 extremely limited.Reliable estimates of sub-national LF incidence rates and baseline population-level immunity are needed

to inform trial site selection and enable successful LF vaccine efficacy trials. In lieu of detailed

geographical measurements, these epidemiological indicators can be modeled from available incidence

and seroprevalence data. Here, we use an epidemiological model to estimate LASV spillover rates and

134 the annual number of community-level LF cases at the $1st$ and $2nd$ administrative levels across West Africa. We provide sub-national estimates of baseline seroprevalence and expected age-specific LF incidence rates to help guide trial selection. We also explore the sensitivity of our estimates to different assumptions of LF immunology, including the proportion of infections that are symptomatic, the level of protection provided by prior infection, and the duration of this protection.

Methods

Model development

 We integrated publicly available epidemiological data into a unified modeling framework for LF in West Africa. We applied this model to investigate key questions regarding vaccine trial design including the expected incidence rates for trial endpoints of disease and infection, the target population (e.g., geographical location, age range, and serostatus of participants), and sample size considerations (number of sites, number of enrollees). The model was adapted from an existing model originally 146 designed to predict spillover of LASV and model reactive vaccination strategies during an LF outbreak.⁶¹ To better understand the magnitude and spatiotemporal distribution of LASV spillover rates and LF incidence in endemic areas, we refined the model to focus on estimating the annual force of infection (FOI), the rate at which susceptible individuals in a population are infected. The updated model also incorporates the potential for seroreversion (seropositive individuals becoming seronegative over time due to antibody waning). FOI estimates at the 1st and 2nd administrative levels were used to estimate seasonal and interannual LF incidence rates across the study region. Rates were investigated in different potential target populations defined by serostatus and age.

a. Epidemiological data

 In our epidemiological model, we included 14 West African countries (Senegal, Gambia, Guinea-Bissau, Guinea, Sierra Leone, Liberia, Côte D'Ivoire, Ghana, Benin, Togo, Nigeria, Niger, Burkina Faso, and Mali),

 plus the administrative districts in Cameroon bordering Nigeria, which encompasses the known range of LASV (Figure 1). Given the extensive spatial heterogeneity in LF incidence, we collated epidemiological 159 data at the 1st and 2nd administrative levels (admin1 and admin2) in each country within the study region. For example, in Nigeria admin1 is the state level and admin2 is the local government area (LGA) level; in Sierra Leone admin1 corresponds to the province level and admin2 is the district level. The epidemiological data included in the study comprised two types: (a) age-stratified serology data to detect evidence of past infection and (b) reports of suspected and confirmed LF cases and deaths in humans. Epidemiological data was initially collated through the end of 2020 from multiple sources (including WHO outbreak reports, ProMED reports, country-level reports, and a literature search) and 166 used in a previous analysis (see Table S1 in Lerch et al. 2022).⁶¹ For the current analysis we searched the same sources for additional datasets through early 2023. We excluded seroprevalence studies from before 1980 or where the location of the study population could not be identified at a sub-national level. We also excluded seroprevalence studies that focused only a specific target population (generally healthcare workers) that may not be representative of the overall population in the study area due to unequal exposure to spillover or human-to-human transmission. All included studies were aggregated to the admin1 and admin2 levels.

 Where possible, case data was categorized into cases of documented or suspected human-to-human transmission, documented or suspected spillover cases, and cases of unknown origin. Cases of documented or suspected human-to-human transmission were excluded from the estimation of spillover rates. Only cases and deaths from 2010-2023 were included in our analysis, because the case/death data were used to estimate the fraction of LF cases that are reported and LF surveillance 178 systems have changed substantially in the past decade.^{5,62} Yearly, age-specific country-level population data from 1960-2015 were obtained from UN World Population Prospects estimates and downscaled to \pm the admin1 and admin2 levels using population raster data from Worldpop.^{64, 63}

181

183 **Figure 1. Study region covering the hypothesized zone of Lassa fever (LF) endemicity.** Areas in orange 184 are (A) 1^{st} administrative level units and (B) 2^{nd} administrative level units that have reported LF cases or 185 deaths from 2010-2023. In some locations, data were only reported at the $1st$ administrative level.

186 *b. Covariate data*

187 To identify population-level covariates associated with LF occurrence, we used spatial datasets of

188 environmental, climate, and socioeconomic variables that have been hypothesized to be associated with

- 189 LF occurrence or transmission.^{8,31,40,42,43,51,53,64,65} These variables included monthly precipitation, monthly
- 190 average temperature, monthly normalized difference vegetation index (NDVI), elevation, latitude,
- 191 Iongitude, travel time to the nearest urban center,⁶⁶ the Healthcare Access and Quality Index (HAQ)

192 based on mortality from causes amenable to personal health care, ⁶⁷ proportion of land cover that was a 193 tropical ecotype⁶⁸, proportion of agricultural land, 69 average forest loss over the past 20 years, 70 an 194 improved housing measure,⁷¹ a poverty index (percentage of households with an International Wealth 195 Index value below 35),⁷² the occurrence of hunting for bushmeat,⁷³ the probability of *Mastomys* 196 occurrence,²⁵ and the probability of LASV occurrence in *Mastomys* (Table S2).²⁵ Each covariate was averaged to the admin1 and admin2 level. Within the study region, the improved housing measure or *Mastomys* occurrence data was missing for some administrative units in northern Senegal, Mali, and Niger, where there is no evidence of LF occurrence, so these administrative units were excluded from our analysis. To reduce the number of variables in our regression models we performed principal component analyses for monthly precipitation, monthly temperature, and monthly NDVI using the 'prcomp' function in R. The first two principal components (PCs) for NDVI explained >90% of the variation in monthly NDVI, and the first three PCs for precipitation and temperature each explained >90% of the variation for these two variables, so these PCs were used in place of the monthly values in subsequent analyses.

c. Model

 A multistep process was used to model LF attack rates from recent epidemiological data: (1) estimation of the recent force of infection (FOI) in administrative units with available seroprevalence data, (2) estimation of the proportion of LF cases and deaths that were detected and reported in administrative units using both seroprevalence data and case/death data, (3) estimation of the annual LASV spillover infection rate in all administrative units with case/death data based on the underreporting estimates from the previous step, (4) projection of the annual FOI for these administrative units based on these spillover rates, (5) calculation of the population-level infection history in each administrative unit based on these FOI estimates, (6) calculation of age-specific infection attack rates and LF incidence rates in each administrative unit under several different scenarios regarding the rates of seroreversion and the

- 216 susceptibility to infection and disease among seropositive and seroreverted individuals (Table 1, Figure
- 217 2). This modeling process was conducted at both the $1st$ and $2nd$ administrative levels. In addition, we
- 218 used statistical and machine learning methods to estimate annual FOI in each administrative unit based
- 219 on the covariates in Table S2 and compared these estimates to the model projections from step 4. This
- 220 analysis was conducted to determine whether environmental variables associated with LF occurrence
- 221 could be used to estimate LASV spillover in the absence of human serology or case data. A brief
- 222 description of each step in this process is provided below, with additional details of the complete
- 223 process provided in the supplementary materials (S1 Appendix).

243 where π is the annual seroreversion rate. Equation (2) simplifies to equation (1) when π = 0. 244 Serology data for FOI estimation was obtained for 24 $1st$ -level administrative units and 53 $2nd$ -level 245 administrative units. Additional details regarding how FOI was estimated from serology data are 246 provided in S1 Appendix.

2. Estimating Country-specific Reporting Fractions

 step 3, we then projected the underlying FOI that would correspond to the estimated infection rate. The projected FOI*ⁱ* for each administrative unit *i* was obtained by minimizing the difference between the number of infections, I*i,* estimated in the previous step and the expected number of infections arising from a given FOI in the reverse catalytic model from equation (2) using the *optim* function in R. This 268 resulted in a posterior distribution of FOI $_i$ for each admin1 and admin2 unit.

5. Estimation of Population-level Infection Histories

 The FOI projections generated from serology and case data in step 4 were then used to simulate 271 population-level infection histories for each admin1 and admin2 unit. For the FOI projections, we drew 272 1,000 samples for each administrative unit from the posterior distribution and computed the proportion of the population that had been infected by age *a* using the catalytic model in equation (1), and the proportion of the population seropositive at age *a* using the reverse catalytic model in equation (2) for the three different seroreversion rates.

6. Estimating LASV Infection and LF Attack Rates

 The inferred population-level infection histories and FOI estimates were then used to compute the expected number of infections in each admin1 or admin2 administrative unit. We examined several different scenarios regarding the risk of seropositive or seroreverted individuals becoming reinfected and developing LF (Table 1). Reinfection of seropositive individuals, as defined by a fourfold increase in antibody titers, was observed in Sierra Leone by McCormick et al. (1987) and in the preliminary results 282 from the ongoing Enable study.^{27,14} In addition, the Enable study reported LF cases among individuals who were seropositive at baseline, indicating that prior infection does not entirely protect an individual 284 from developing disease if they are reinfected (unpublished data).¹⁴ Therefore, we considered three scenarios for the susceptibility of seropositive individuals to symptomatic infection: (a) no risk, (b) a 286 reduced risk informed by the rates of infection observed in seronegative vs. seropositive individuals observed by McCormick et al. (1987) and Enable (relative risk (RR) = 0.53), or (c) a reduced risk informed by the relative rates of LF cases observed in individuals who were seropositive vs. seronegative at baseline in the Enable study (RR=0.36).

 Table 1. Immunological parameters included in model sensitivity analysis, and the low, medium, and high values considered for each parameter. Lassa fever relative risk values are in comparison to fully susceptible individuals with no history of LASV infection.

 Although simple reverse catalytic models generally assume that seroreverted individuals are susceptible to reinfection, an individual may still have protection against developing moderate or severe disease even if their antibody titers have dropped below the detectable limit. At present this possibility has not been addressed for LASV, so we considered two scenarios: (a) seroreverted individuals are completely susceptible to reinfection and illness, and (b) seroreverted individuals can be reinfected but have a reduced probability of developing LF based on the reduced rate of reinfection experienced by seronegative vs. seropositive individuals (RR=0.53). Including our three seroreversion rate scenarios, we therefore consider a total of 18 (3x3x2) scenarios regarding the role of immunity in modulating susceptibility and influencing LF attack rates. The expected annual number of infections in administrative unit *i* were calculated from the FOI*ⁱ* using the reverse catalytic model in equation (2) for each of the 18 different scenarios at both the admin1 and admin2 levels. The number of infections was multiplied by the symptomatic probability (20%) to obtain an estimate of the expected annual number of LF cases in each administrative unit. To account for the observed seasonality in human LF cases, we fit a beta distribution to the timing of reported LF cases in Nigeria, Liberia, and Sierra Leone, and simulated the timing of LF cases as a random

draw from that distribution. For countries where we could not estimate seasonality, we assumed an

- average of the observed seasonality in Nigeria, Liberia, and Sierra Leone.
- *Modeling the FOI from covariate data*

There is a large degree of uncertainty in the estimated spillover rates for administrative units that have

reported only a small number of LF cases due to the large proportion of asymptomatic infections and

low reporting probabilities. Therefore, we used several statistical models to explore the relationships

between our FOI estimates from step 4 and several key spatial covariates (Table S2). These statistical

316 regression models were fit to the projected FOI_i estimates from administrative units with either serology

data or reported LF case/death data (N=77 of 164 admin1s, N=372 of 1,375 admin2s). The fitted models

were then used to predict FOI in the administrative units with no serology or case data.

Given that we have limited historical data and high uncertainty in our projected FOI estimates, we

considered eight different statistical models, as well as a null model with a single FOI estimated across

all administrative units. For each seroreversion scenario, we generated an ensemble model projection of

FOI in each admin1 or admin2 from the eight statistical models. Ensemble weights for each of the eight

models were calculated based on the performance of the individual model at predicting data withheld

from the model fitting step using a ten-fold cross-validation technique. Further details on the individual

statistical models and the ensemble approach are presented in S1 Appendix.

Results

Literature review

Thirty-one papers were selected for in-depth literature review. Topics of interest were Lassa serology (n

329 $= 12$), rodent epidemiology (n = 10), environmental risk factors and seasonality (n = 5), and LF

incidence/symptomatic rates (n = 4). Studies took place in Sierra Leone (n = 7), Guinea (n = 7), Nigeria (n

331 = 10), Ghana (n = 1), and Mali (n = 3). Three studies included all LF cases in Africa or globally (including

 imported cases). Most studies were published in the last 10 years (n =21). Seven studies were published between 2000 and 2013, and three studies were from before 2000. LASV IgG seroprevalence varied from 4% to 60%; in general, rates were higher in forest and savannah regions and lower near the coast 335 and in the highlands.⁴⁰⁻⁴³ Seroprevalence in rodents is similarly variable, with IgG positivity between 6- $52\%/^{29,53-56}$ and PCR positivity between 1-87%.^{58,59} One study in Guinea found that individual villages showed some interannual variation in rodent seropositivity, but that all villages studied maintained at 338 least 20% positivity from year to year.⁵⁷ Studies of seroreversion rates in Sierra Leone and Mali found 6 339 and 3% of seropositive individuals, respectively, reverted to seronegative in a given year.^{23,29} It is typically assumed that 80% of Lassa fever infections are asymptomatic, but data supporting this assumption is extremely limited. All studies included are shown in Table S1. *FOI estimates from serology* 343 The FOI was estimated from serology data available from 1980-2023 for 24 1st-level administrative units $-$ and 53 2nd-level administrative units. FOI was estimated for at least one administrative unit in Côte d'Ivoire, Ghana, Guinea, Liberia, Mali, Nigeria, and Sierra Leone (Figure 3). Under the assumption of no seroreversion, the highest FOI at the admin1 level was in Ondo State, Nigeria (0.036/yr; 95% Credible Interval (CrI): 0.027-0.047) and the highest FOI at the admin2 level was in Moyamba District, Sierra Leone (0.063/yr; 95% CrI: 0.042-0.090) followed by Ose LGA in Ondo State, Nigeria (0.052/yr; 95% CrI: 0.037-0.071). The FOI estimates assuming annual seroreversion rates of 3% or 6% were higher than FOI estimates without seroreversion. Ondo State, Nigeria remained the highest FOI at the admin1 level, with the estimate increasing to 0.065 (95% CrI: 0.047-0.086) with a 3% seroreversion rate and 0.099/yr (95% CrI: 0.071-0.133) with a 6% seroreversion rate. At the admin2 level Ose LGA, Nigeria had the highest FOI estimate with 3% or 6% seroreversion rates, followed by Moyamba District, Sierra Leone and Esan West LGA in Edo State, Nigeria.

Estimates of underreporting

Estimates of the probability that a LASV infection would be reported as an LF case were estimated for

- each of the countries with serology and LF case data (Côte d'Ivoire, Ghana, Guinea, Liberia, Mali, Nigeria,
- and Sierra Leone). In addition, we estimated the average reporting probability across the study region,
- which was used to estimate LASV infections and FOI in countries that did not have serology data. Due to

381

382

385

386 *Estimates of FOI from individual statistical and ensemble models*

387 Among the statistical and machine learning models we explored to characterize the explanatory value of 388 the covariates in Table S2, the random forest model provided the best fit to the projected FOI estimates 389 at the admin1 level (r^2 =0.95), followed by the boosted regression model (r^2 =0.78; Figure 5, Figure S3). At 390 the admin2 level, the random forest model again provided the best fit (r^2 =0.96), followed by the linear

391 model with interactions (r^2 =0.83; Figure S4). The Gaussian Markov random field (GMRF) models with covariates also fit the projected FOI estimates better than GMRF models without covariates (Figures S3- S4) suggesting that the covariates provide some useful information. At the admin1 level, the most important covariates in the random forest model were longitude, travel time to the nearest urban center, and the Healthcare access and quality index (HAQ) (see Table S3 for full list of covariate importance). center, and the estimated probability of LASV presence in *Mastomys natalensis* (Table S4). At the admin2 level, the most important covariates in the random forest model were longitude, HAQ, 398 and the 2^{nd} precipitation PC (Table S5). The performance of the model predictions on data held out of 399 the regression for model validation was much lower for the $1st$ administrative level, with random forest 400 providing the best fit to the testing data (r^2 =0.32), suggesting that the models are overfitting to the training dataset (Figure S5). The cross-validation performance of most regression models was better at 402 the 2nd administrative unit, with the random forest model providing the best fit (r^2 =0.76), and the 403 boosted regression and GMRF models with and without covariates all maintaining an r^2 >0.70 (Figure S6). The low ratio of data points per covariate at the admin1 level may explain the poor cross-validation performance relative to the admin2 level (N=77 for admin1 vs. N=372 for admin2). Our ensemble model consisted of a weighted combination of the FOI predictions of each individual 407 statistical regression model, along with a noise term. The ensemble model FOI estimates at the 2^{nd} administrative unit (Figures S7-S9) show much less spatial heterogeneity than the projected FOI estimates from LF case data and reporting probabilities (Figure 4B). This largely results from the higher weighting of the GMRF models, which include spatial smoothing (45.7% combined among the four GMRF models). This spatial smoothing results in lower FOI estimates in the few projected Nigerian hotspots, and lower within- and among-country variation in FOI estimates overall. Further details on the results of the statistical and ensemble modeling are presented in the supplement (SI Results).

 Figure 5. Scatterplots showing the relationship between the statistical regression predictions of FOI on the x-axis versus the FOI estimates projected from LF case data and reporting probabilities for the best performing statistical models included in our analysis. (A) Results of random forest model, and (B) results of boosted regression tree model. Plots are restricted to FOI estimates that were used in model 421 fitting and do not include data held out for model validation. Results are for the $1st$ administrative level and a 6% seroreversion rate. Grey lines around points represent error bars for both direct and regression estimates of FOI values.

LASV infection attack rates and LF incidence rates

Due to the positive association between the assumed seroreversion rate and FOI, the highest LASV

infection attack rates and LF case incidence rates occurred in scenarios with a seroreversion rate of 6%.

- For a given seroreversion rate, LF case incidence rates were lowest when seropositive individuals were
- assumed to be protected from infection, intermediate when they had a relative risk of 0.36 for

 developing LF compared to seronegative individuals, and highest when they had a relative risk of 0.53 for reinfection and disease. When seroreverted individuals were assumed to have partial protection against LF, incidence rates were lower than when seroreverted individuals were assumed to be fully susceptible. Therefore, estimated LF incidence rates were highest when we assumed that seroreversion was frequent (6%), and that both seroreverted and seropositive individuals remained susceptible to infection and disease.

Due to the spatial heterogeneity in our FOI estimates, the highest LF incidence rates were found at the

admin2 as opposed to the admin1 level. No admin1 units had an LF incidence rate of greater than 10 per

1,000 (1%) with a 0% or 3% seroreversion rate, and only Ondo State in Nigeria had an LG incidence

rate >10/1,000 at a 6% seroreversion rate based on our projected FOI estimates (Table 2 and Tables

S7,S9). In general, there was a wider range of annual LF incidence rates with the projected FOI

estimates than the ensemble model FOI estimates, due to the smoothing effects of the ensemble model.

For example, no Nigerian states were in the top-20 using the ensemble model estimates despite Ondo,

Ebonyi, and Edo States all being in the top-20 based on the projected FOI estimates. Due to the over-

smoothing effect observed in the ensemble model, we focus on LF incidence rates derived from the

projected FOI estimates in the rest of our results.

446 At the $2nd$ administrative level, LF incidence rates calculated from projected FOI estimates were >10 per 1,000 for several administrative units with seroreversion rates of 3% or 6%, but not 0% (Table 3 and Tables S8,S10). While the influence of different assumptions regarding the susceptibility of seropositive and seroreverted individuals to LF was minor at lower incidence rates, their impact is more apparent for the admin2 units with the highest incidence rates (Table 3). For example, for Ose LGA, Nigeria, the admin2 with the highest FOI, the median annual LF incidence rate increased from 9.7 per 1,000 when seropositive individuals had full immunity and seroreverted individuals had partial protection, to 12.4 per 1,000 when seropositive individuals were fully immune but seroreverted individuals had no

- 454 protection, to 24.7 per 1,000 when seropositive individuals were only partially immune and
- 455 seroreverted individuals had no protection. Four admin2 units (two in Sierra Leone, one in Nigeria, and
- 456 one in Guinea) had LF incidence rates <10 per 1,000 when seropositive individuals were fully protected,
- 457 but incidence rates above 10 per 1,000 when we assume seropositive individuals were susceptible to
- 458 reinfection and illness.

459 **Table 2. The top 20 highest annual Lassa Fever (LF) incidence rates (per 1,000) at the 1st administrative level when the seroreversion rate is**

- 460 **6%.** LF rates are calculated using the projected force of infection (FOI) estimates under different assumptions regarding the level of immunity in
- 461 seropositive and seroreverted individuals. Values in parentheses represent 95% prediction intervals.

Table 3. The top 20 highest annual Lassa Fever (LF) incidence rates (per 1,000) at the 2nd 463 **administrative level when the seroreversion rate is**

464 **6%.** LF rates are calculated using the projected force of infection (FOI) estimates under different assumptions regarding the level of immunity in

465 seropositive and seroreverted individuals. Values in parentheses represent 95% prediction intervals.

466

- The age-specific infection histories calculated using the projected and ensemble FOI estimates can also
- be used to calculate annual LF incidence rates for specific age groups. LF incidence rates decrease with
- age as the likelihood of a previous infection and at least partial protection from infection and disease
- increases (Figure 6).

administrative units with the highest incidence. Incidence calculated using projected FOI estimates from

LF case data and estimated reporting probabilities and assuming a seroreversion rate of 6%, seropositive

- individuals have partial protection from reinfection and disease (RR=0.53), and seroreverted individuals
- are partially protected (RR=0.36) from reinfections and disease. Boxes represent interquartile range

(IQR) and lines the 95% prediction interval.

Interannual variability in incidence

 The 1,000 samples from the posterior distribution of the projected FOI estimates incorporate both the uncertainty and the interannual variability in our FOI estimates and the corresponding annual LF incidence rates. Figure (7) provides an example of the variability in LF incidence rates (per 1,000) for the nine highest incidence admin2 units under a scenario where the seroreversion rate is 6%, seroprotected individuals have a relative risk = 0.36 of developing LF if infected, and seroreverted individuals are also partially susceptible to reinfection and disease (relative risk = 0.53). The variation in LF incidence rates is highest for locations where FOI was estimated from LF case data and reporting probabilities only (no serology data) because these estimates incorporate uncertainty in reporting probabilities in addition to interannual variability. Locations where FOI estimates were informed by serology data, such as Macenta and Faranah Districts in Guinea and Sikasso District in Mali, have lower uncertainty. However, even in these locations, the estimated annual LF incidence rate can vary by 10-50% from year-to-year. For example, the narrowest estimated range in annual LF incidence is in Faranah District, Guinea with a median annual incidence of 7.0 per 1,000 (95% CrI: 6.4-7.7), where 95% of years would be expected to be within +/- 10% of the median value. Esan West LGA in Edo State, Nigeria has a median LF incidence rate of 13.0 per 1,000 (95% CrI: 10.0-16.2), with variability of +/- 25% from the median. An example of a location with a high uncertainty and interannual variability is Ose LGA in Ondo State, Nigeria which has a median annual LF incidence rate of 22.0 per 1,000 (95% CrI: 14.1-32.0) with variability of approximately +/- 50%.

Seasonality

 Reported LF cases in Nigeria and Liberia, and to a lesser extent in Sierra Leone, show a clear seasonal pattern with a peak in cases in January to March (Figure 8). Liberia also shows a secondary peak later in the year, although this may be part of the January peak in cases. In Sierra Leone, LF cases peak in March, but there appears to be considerable transmission throughout the year.

 Figure 7. Posterior distribution of annual Lassa fever (LF) case incidence rates in the nine highest admin2 units. LF incidence estimates are based on projected FOI estimates from LF case data and reporting probabilities. Results presented are for a scenario with 6% seroreversion rate, partial protection against reinfection and disease in seropositive individuals (relative risk = 0.36), and partial protection against reinfection or disease among seroreverted individuals (RR = 0.53). The red dashed line is the median of the posterior distribution.

 Figure 8. Seasonality of LF incidence in (A) Nigeria, (B) Liberia, (C) Sierra Leone, and (D) averaged across these three countries. Blue line represents a generalized additive model with a cyclical cubic regression spline fit to the weekly fraction of annual cases (grey represents the 95% confidence interval).

Discussion

 Using a modeling framework that incorporated LF serology, case, and death data, we found considerable spatial variation in LASV spillover and LF incidence across West Africa, with the highest incidence rates in areas within Nigeria, Sierra Leone, and Guinea. We also estimate that as few as 0.2% of LASV infections are captured by current surveillance systems. These results represent the most extensive and geographically detailed estimates of LF surveillance and incidence across the entire endemic range in West Africa to date. Our LF incidence estimates were sensitive to assumptions about the duration and strength of infection-induced immunity. LF incidence rates were particularly sensitive to the rate of seroreversion among previously infected individuals because this value affects both susceptibility to reinfection and the interpretation of serology data. Our spatial LF incidence rate estimates, along with the interannual and seasonal variability in these estimates, could be used to target high incidence areas suitable for inclusion in a vaccine trial and estimate expected trial event rates. However, the uncertainties in our LF incidence estimates highlight critical knowledge gaps regarding the number of asymptomatic and mild LASV infections that go undetected and the extent to which these infections provide long-lasting immunity. 539 Our estimates of LF incidence rates indicate that there are few $1st$ or $2nd$ level administrative districts where the predicted attack rate would be at least 1% as is desired for vaccine field trials. Our estimates assumed that 20% of LASV infections are symptomatic, as frequently reported. However, if substantially fewer than 20% of infections are captured by active syndromic surveillance, as has initially been reported for the Enable study, then none of these districts would be likely to reach an LF attack rate of 544 1%.¹⁵ Therefore, ensuring sufficient statistical power may require a large increase in the number of individuals enrolled in a field trial. One alternative to increasing the size of the study population would be to use protection against infection as a primary endpoint instead of protection against symptomatic disease. Due to the high number of asymptomatic infections, active monitoring for seroconversion—

 while more difficult and costly than symptom-based surveillance methods—would increase the number of expected endpoints without increasing the size of the study population. Another option would be to adopt a responsive trial design that employed ring vaccination or a similar strategy to focus study efforts on locations with active transmission. Given the focal nature of LF spillover to humans, and the substantial interannual and seasonal variation in incidence, such a strategy would ensure that areas of 553 active transmission are targeted.^{23,40,46}

 Trial site selection also needs to account for the baseline seroprevalence in a target population as that will influence the fraction of the population that is susceptible to infection. Locations with high baseline seroprevalence may experience few LF cases even if LASV is actively circulating in the rodent population. However, there is considerable uncertainty about the duration of immunity to LASV, and several studies 558 suggest that seroreversion is relatively common.^{23,24,76} Assumptions about the seroreversion rate had the largest impact on estimated LF incidence among the different immunological scenarios included in our analysis. Without seroreversion, our FOI estimates were too low for the resulting annual LF incidence rates to exceed 10 per 1,000 (1%) anywhere within the study region. Further results from the longitudinal serology samples from the Enable study should help refine our understanding of seroreversion rates and whether they vary by location or age.

 The level of protection against reinfection and disease among both seropositive and seroreverted individuals also influenced expected LF incidence rates in our model, with higher levels of protection against disease resulting in lower expected incidence rates. The different scenarios explored in our model could be leveraged to select the most plausible scenario for estimating event rates in a particular site and target population. This model can also be used to explore how LF incidence rates vary by both age and serostatus under different assumptions regarding how serostatus affects susceptibility to (re-)infection and disease, which can help to inform selection of a target population and trial size calculations. Results from the Enable study will also help refine future model scenarios regarding the
role of immunity and serostatus, as the study will report relative LF incidence rates among individuals who were seropositive or seronegative at baseline (or in the previous sampling period) and may also be able to capture the reinfection and LF incidence rates among individuals who serorevert over the course of the study.

 Our model projections represent the most extensive and geographically detailed estimates of LF surveillance and incidence across the entire endemic range in West Africa to date. Previous modeling studies have generated fine-scale maps of the likely distribution of LASV, but have not estimated LF 579 incidence rates or seroprevalence in the human population.^{26,28,51} Basinski et al. (2021) modeled LASV risk in rodents and then fit a regression model of this risk measure against historical seroprevalence data 581 to generate fine-scale estimates of LASV seroprevalence in the human population.²⁵ However, their study did not incorporate LF incidence data or account for certain epidemiological features of LF in generating these estimates. Our projected FOI estimates and modeled annual LF incidence rates indicate that Sierra Leone, southern Guinea near the border with Sierra Leone and Liberia, and a few high incidence regions within Nigeria would likely yield the highest LF case incidence rates during a vaccine 586 trial. Comparisons of our estimates at the $1st$ and $2nd$ administrative levels show that there is 587 considerable spatial heterogeneity among different admin2s within the same $1st$ administrative unit 588 (particularly in Nigeria, Guinea, and Mali), and therefore predictions from the 2nd administrative level are likely to be more useful for site selection.

590 The 2nd administrative level FOI estimates that were projected from LF case data and reporting probabilities appear to be more accurate than the FOI estimates from our ensemble model that used spatial covariates to improve model predictions in areas lacking data, particularly in areas that are projected to have the highest incidence. The ensemble model smoothed over the spatial heterogeneity in FOI to an extent that lowered the incidence rate in some regions with a high number of reported cases and deaths, particularly in Edo and Ondo states in Nigeria. Therefore, at present, the projected FOI

 estimates likely provide more reliable estimates for field trial site selection than the estimates from the ensemble model. Further model refinements, including model selection techniques to determine the most influential spatial covariates, and further model validation using serology data from the literature and forthcoming Enable results could improve the ensemble model predictions. However, regression analyses and ensemble modeling methods are most useful for predicting incidence where data is sparse and the relationship between the response variable (incidence) and the explanatory variables is strong. There is still a lot of uncertainty about what conditions distinguish areas with high LASV spillover rates from areas with similar environmental conditions and where *Mastomys spp.* are present, but spillover is rare or nonexistent. Hopefully additional field studies and serological surveys will help explain these discrepancies, but at present we lack the ability to predict the occurrence of LF at a fine spatial scale outside of the well-documented hotspots of transmission. In the absence of this ability, our admin2 incidence estimates could help identify broader regions to target for vaccine trials, and baseline serology surveys can be conducted at the local level to confirm LASV spillover in the area. In particular, evidence of past infection in younger children would indicate recent transmission. Our modeling framework did incorporate estimation of country specific LF case and death reporting

 probabilities, but it also seems unlikely that areas within the study region that haven't reported any LF cases or deaths have as high a burden of LF as the known hotspots in Nigeria, Sierra Leone, Guinea, and Liberia. The burden of LF outside of the known hotspots is an important outstanding question, but it is likely that observed spatial patterns of reported LF cases and deaths reflect at least some important differences in the spatial distribution of the disease. Although mild and moderate LF cases are difficult to distinguish from other febrile illnesses such as malaria, severe LF cases requiring hospitalization have been associated with nosocomial outbreaks in Nigeria, Sierra Leone, and Liberia, but not in other areas 618 West Africa.⁷⁷⁻⁷⁹ A seroprevalence study in multiple locations within Ghana, and preliminary 619 seroprevalence results from the Enable site in Benin also suggest that transmission is lower in these

620 countries than it is in the known hotspots for transmission.⁵¹ However, high seroprevalence were recently observed in southern Mali, suggesting that there may be undocumented areas of LF incidence 622 outside of the historical hotspots. $80,81$ *Model limitations* Despite recent efforts to prioritize the study of LF, there are still many unknowns, which limit the predictive power of our model. LF incidence rates vary significantly based on many confluent factors, and the limited number of longitudinal and broad scale studies makes it difficult to draw significant conclusions about the risk of LF in a particular time and place. Our model does not account for non- epidemiological considerations that may influence site selection, such as the strength of the existing local or national health infrastructure system, political stability, or cultural barriers to trial implementation. However, the model results can be used to rank potential trial sites by expected LF incidence rates and seroprevalence (e.g., expected serostatus by age group), and then other factors can be used to select appropriate trial sites from locations with suitable characteristics. The current model also cannot estimate the geographical variation in expected LF incidence rates within 634 a given 2nd administrative area. Past serology studies in Guinea and Sierra Leone, and preliminary results from the Enable study, show that seroprevalence rates can vary significantly from village to village 636 within the same state or district.^{23,40,46} However, the identification of risk factors associated with small- scale variations in seroprevalence, infection attack rates, or LF incidence have been inconsistent, limiting our ability to predict high incidence areas within a given administrative region. The Enable study will provide some additional context on this finer-scale heterogeneity in attack rates and incidence due to the large sample size and the relatively high number of villages sampled. However, the targeted criteria used for site selection may limit our ability to extrapolate the study results beyond these study sites. Variation in our estimated LF incidence rates for a given location results from a combination of

parameter uncertainty and interannual variability in reported LF cases and deaths. Longitudinal

- serological or incidence data was insufficient to explicitly estimate interannual variability across the
- study area.
- *Conclusions*

Acknowledgements

- The authors thank CEPI for insights into current planning considerations for Lassa fever vaccine trials and
- an overview of the preliminary results from the ENABLE study. We thank Melissa Wynn, Carrie Mills,
- Kevin Sprurgers, and Lovelyn Charles at Emergent Biosolutions for help with coordinating research
- efforts.
- **Author Contributions**
- Conceptualization: SMM, NED, STS
- Data Curation: SMM, ER, SMG
- Formal Analysis: SMM
- Funding Acquisition: STS
- Investigation: SMM
- Methodology: SMM, NED, STS
- Project Administration: SMG, STS
- Resources: SMM
- Software Programming: SMM
- Supervision: STS
- Validation: SMM
- Visualization: SMM, ER
- Writing Original Draft Preparation: SMM, ER
- Writing Review & Editing: SMM, ER, SMG, NED, STS

Supporting Information

- **S1 Appendix**
- **Model Details**
- **1.** *Estimating the Force of Infection from Serology Data*
- For administrative units with serology data binned by age group, we calculated the likelihood of the FOI
- 690 (λ) based on the number of individuals between ages a_1 and a_2 (the upper and lower bounds of the age
- group) who tested positive, *P(a1:2),* out of the total number sampled, *T(a1:2)*. The likelihood was
- 692 calculated for each age between a_1 and a_2 assuming a binomial distribution, $P(a_{1:2}) \sim$
- 693 *Binomial(T(a_{1:2}),p(a))* where $p(a)$ is the probability that an individual was seropositive as determined by

equation (2). We then took a weighted average of the likelihood for each age group, with the weighting

- determined by the proportion of the population in that administrative unit in each age within the age
- group. We calculated the likelihood of the overall FOI (λ*i*) in administrative unit *i* by summing the logs of
- the binomial probabilities of *Pi(a1:2)* across all age groups in a given seroprevalence dataset. The
- likelihood of a given FOI (λ*i*) for each administrative unit *i* was calculated across a range of values
- 699 between 10^{-6} and 10^{1} . We then fit a gamma distribution using the *optim* function in R to estimate shape
- 700 and scale parameters representing the mean and variance in FOI (λ_i) , and these parameters were used
- as inputs to the subsequent steps in the modeling framework.
- *2. Estimating Country-specific Reporting Fractions*

 For each administrative unit where the FOI was estimated from serological data in the previous step, we estimated the fraction of LF infections from 2010-2023 that went unreported based on the discrepancy between reported LF cases and deaths and the number of infections predicted by the FOI estimates from those sites under the three different seroreversion scenarios. We assume that all individuals within an administrative unit are at risk of LASV infection and that each individual has the potential to fall into

 one of three categories during the study period: an observed LF case, an observed LF death, or unobserved. The unobserved category includes both individuals who were not infected and individuals who had an unobserved LASV infection (either because it was an asymptomatic infection or was an LF case/death that was not reported). We therefore modeled the distribution of person-years from 2010- 2023 across these three categories: observed deaths, D; observed cases, C; and the total unobserved 713 person-years, N. For administrative unit *i*, the total unobserved person-years, N_i , is calculated as $N_i = Y_i -$ *Ci* – *Di*, where *Yi* = Σ*Popi* is the sum of the annual population sizes from 2010-2023. The probability that a person of age *a* in year *y* would die from LF and be reported as such was,

716
$$
\Pr(reported death, a | \lambda_i, U_i, \rho_D, \pi) = (1 - p(a)) \frac{\lambda}{\lambda + \pi} (1 - e^{-(\lambda + \pi)}) (1 - U_i) \rho_D, \quad (A1)
$$

717 where U_i is the proportion of infections that are unobserved in location *i* and ρ_D is the proportion of 718 observed infections that result in death. Equation A1 represents the probability that an individual was 719 susceptible at time *y*, and subsequently becomes infected in year *y* (based on the FOI, λ) and 720 experienced an infection that was both observed and resulted in death. The probability of a reported 721 case was the same as equation (A1) but with ρ_D replaced by 1 – ρ_D . The probability of an unobserved 722 person-year, Pr(*unreported person~year, a* | λ_i , U_i , π), takes into account the multiple ways in which 723 a person-year would not result in a reported death or case, including currently being immune due to a 724 past infection, by not being infected during the study time period from 2010-2023, or by being infected 725 in year *y* but not being reported. From *Pr(reported death)*, *Pr(reported case)*, and *Pr(unreported person-726 year)* we calculate the probability of D_i , C_i , and N_i among Y_i total person-years, Pr(D_i , C_i , $N_i | \lambda_i$, U_i , ρ_D), 727 using a multinomial distribution. Given estimates of λ_i from step 1, we used this distribution to estimate 728 the parameter *U_i* for each *i*, and country-specific values for ρ_p . The log likelihood of *U_i* and ρ_p was 729 calculated by summing the logs of the probabilities from Pr(D_i , C_i , N_i $|\lambda_i$, U_i , ρ_D) assuming 730 noninformative priors between 0 and 1 for all U_i and a beta-distributed prior for ρ_D with shape

 parameters 2.05 and 6.85. The posterior distributions of the parameters were then sampled using the BayesianTools package in R.

 To extrapolate reporting fractions beyond the few administrative units with both serological and case/death data, we fit a Dirichlet distribution to the posterior predictions of the proportions of infections that result in a reported death, a reported case, or an unreported infection. For each draw *j* from the posterior, the proportions of reported deaths, reported cases, and unreported infections were 737 calculated respectively as $(1 - \bar{U}_i)\rho_{D,i}$, $(1 - \rho_{D,i})$, and \bar{U}_i ; with $\bar{U}_i \rho_{D,i}$ representing the country- specific averages across all sites *i* within a country for each draw *j* from the posterior distribution. The corresponding Dirichlet parameters associated with reported cases, reported deaths, and unreported 740 infections were α_D , α_C , and α_U . We estimated these Dirichlet parameters by maximum likelihood using the *optim* function in R, treating posterior predictions of the proportion of infections that result in a reported death, a reported case, or an unreported infection as data points drawn from the Dirichlet distribution being fitted.

3. Estimating LASV spillover rates

 For each administrative unit we next estimated the total number of annual infections, *Ii,* based on the reported LF cases and deaths from 2010-2023 along with the estimated reporting probabilities from the previous step. The likelihood of a given number infections, *Ii,* in administrative unit *i* was calculated using the Dirichlet-multinomial probability of obtaining the reported deaths, *Di*, and reported cases, *Ci*, and *Ii - Di - Ci* unobserved infections following *Ii* draws of those categories according to Dirichlet-distributed 750 probabilities with parameters α_D , α_C , and α_U from step 2:

751
$$
L(I_i|C_i, D_i, \alpha_D, \alpha_C, \alpha_U) = Pr(D_i, C_i, I_i - D_i - C_i|I_i, \alpha_D, \alpha_C, \alpha_U).
$$

 We normalized the likelihoods from this equation across all values of *Ii* to obtain posterior probabilities of each *Ii,* which we used to obtain a set of posterior samples of *Ii* for each admin1 and admin2 unit.

4. Projecting the Force of Infection from estimated LASV spillover rates

6. Estimating LASV Infection and LF Attack Rates

 The population-level infection histories and FOI estimates were then used to compute the expected number of infections in each administrative unit i. We examined several different scenarios regarding the risk of seropositive or seroreverted individuals becoming reinfected and developing LF as described in the *Methods* section of the main text. The expected annual number of infections in administrative unit *i* were calculated from the FOI*ⁱ* using the reverse catalytic model for each of the 18 different scenarios at both the admin1 and admin2 levels. The number of infections was multiplied by the

symptomatic probability (20%) to obtain an estimate of the expected number of LF cases in each

- administrative unit.
- *Modeling the Force of Infection from Covariate Data*

 The estimation of LASV spillover rates and the projection of the FOI from these spillover rates was performed for all admin1 and admin2 administrative units within the study region. However, LF cases or deaths have been reported in <50% of administrative units within the region (Figure 1), and infection estimates for these administrative units without any reporting are contingent on our estimated underreporting probabilities. In addition, there is also a large degree of uncertainty in the true spillover rate in administrative units that have reported only a small number of LF cases due to the large proportion of asymptomatic infections and low reporting probabilities. Therefore, we used several 786 statistical models to explore the relationships between our FOI; estimates from step 4 and several key 787 spatial covariates (Supplemental Table S2). These models were fit to the projected FOI_i estimates from 788 administrative units with either serology data or reported LF case/death data (N=77 of 164 admin1s, 789 N=372 of 1375 admin2s). The fitted models were then used to predict FOI in the administrative units with no serology or case data. Given that we have a relatively small dataset and high uncertainty in our projected FOI estimates, we considered eight different models, as well as a null model with a single FOI estimated across all administrative units. The first two models were linear regression models with or without two-way interaction terms between covariates. We also considered four different Gaussian Markov random field (GMRF) models: two with no covariates and two with linear effects of the covariates. GMRF models use a minimum mean squared error linear prediction with spatial covariance 796 for spatial prediction or interpolation⁸². The GMRF models with or without linear effects for the 797 covariates were run at two spatial resolutions: a low resolution (k=10 free parameters for admin1 and k=25 for admin2) or high resolution (k=40 for admin1 and k=100 for admin2). The seventh model was a

 random forest model implemented in R with the *randomForest* package. The eighth, and final, model was a boosted regression model implemented in R with the *gbm* package.

For each of the models we took 1000 samples from the posterior distributions of FOI*ⁱ* from step 4 and

802 regressed log_{10} FOI against the covariates (where applicable), resulting in 1000 separate fits per model.

The predicted values for both the fitted and unfitted administrative units from each model were then

treated as point estimates to construct a set of 1000 posterior samples of FOI*ⁱ* for each administrative

unit and each model.

Ensemble model

For each seroreversion scenario, we generated an ensemble model projection of FOI in each admin1 or

808 admin2 using a form of stacked generalization⁸³. Stacked generalization treats the eight statistical

models as being at one level and uses the first-level models to generate a higher-order model that

weights the predictions of the first-level models into its own prediction. The performance of each first-

811 level model was assessed using a ten-fold cross-validation technique, with 90% of the data partitioned

into the training set to fit the model, and the remaining 10% withheld for model validation. This process

was performed ten times, with a different 10% of the dataset withheld for validation each time. Model

performance was then assessed based on the model predictions on the withheld data and ensemble

weights for each model were calculated based on relative model performance.

S1 Results

1. Statistical and ensemble model results

Ensemble model

837 Our ensemble model consisted of a weighted combination of the FOI predictions of each individual 838 statistical regression model, along with a noise term. Each model weight was calculated based on its negative marginal log likelihood in ten-fold cross-validation. Assuming a 6% seroreversion rate, the 840 highest model weight for the admin1 ensemble model was the random forest model (43.7%), followed

 by the boosted regression model (35.1%), the high resolution GMRF with covariates (9.9%), the high 842 resolution GMRF without covariates (6.0%), and the low resolution GMRF with covariates (5.2%). For the admin2 ensemble model the model weights of at least 5% in decreasing order were: the random forest model (46.3%), the high resolution GMRF with covariates (15.1%), the low resolution GMRF without covariates (13.7%), the high resolution GMRF without covariates (11.5%) and the boosted regression model (5.8%).

Ensemble model estimates of FOI at the $1st$ administrative level show a similar spatial pattern and

magnitude to the projected FOI estimates (Figure 4A), with predicted high FOI areas in Sierra Leone,

849 Guinea, and southern Nigeria (Figure S9A). However, there are admin1 units that did not report any LF

cases or deaths from 2010-2023, and therefore had low projected FOI values, but are predicted by the

851 ensemble model to have high FOI values. The ensemble model FOI estimates at the 2^{nd} administrative

unit (Figure S9B) show much less spatial heterogeneity than the projected FOI estimates from LF case

data and reporting probabilities (Figure 4B). This largely results from the higher weighting of the GMRF

models, which include spatial smoothing (45.7% combined among the four GMRF models). This spatial

smoothing results in lower FOI estimates in the few projected Nigerian hotspots, and lower within- and

among-country variation in FOI estimates overall.

1. Table S1. Papers selected for in-depth literature review.

Table S2. Population-level covariates with a potential association with LF occurrence.

Table S3. Variable importance in the Random Forest model at the 1st administrative level. Variable

importance calculated with median projected FOI as the response variable.

Table S4. Variable importance in the Boosted regression tree model at the 1st administrative level.

Variable importance calculated with median projected FOI as the response variable.

Table S5. Variable importance in the Random Forest model at the 2nd administrative level. Variable

importance calculated with median projected FOI as the response variable.

Table S6. Coefficient estimates and t-values for the linear model with interaction terms at the 2nd

Table S7. The top 20 highest annual Lassa Fever (LF) incidence rates (per 1,000) at the 1st administrative level when the seroreversion rate is 0%. LF rates are calculated using the projected force of infection (FOI) estimates under different assumptions regarding the level of immunity in seropositive and seroreverted individuals. Values in parentheses represent 95% prediction intervals.

Table S8. The top 20 highest annual Lassa Fever (LF) incidence rates (per 1,000) at the 2nd administrative level when the seroreversion rate is 0%. LF rates are calculated using the projected force of infection (FOI) estimates under different assumptions regarding the level of immunity in seropositive and seroreverted individuals. Values in parentheses represent 95% prediction intervals.

77

Table S9. The top 20 highest annual Lassa Fever (LF) incidence rates (per 1,000) at the 1st administrative level when the seroreversion rate is 3%. LF rates are calculated using the projected force of infection (FOI) estimates under different assumptions regarding the level of immunity in seropositive and seroreverted individuals. Values in parentheses represent 95% prediction intervals.

Table S10. The top 20 highest annual Lassa Fever (LF) incidence rates (per 1,000) at the 2nd administrative level when the seroreversion rate is 3%. LF rates are calculated using the projected force of infection (FOI) estimates under different assumptions regarding the level of immunity in seropositive and seroreverted individuals. Values in parentheses represent 95% prediction intervals.

Figure S1. Maps of FOI projections from LF case/death data and reporting probabilities at the (A) 1st and (B) 2^{nd} administrative levels with seroreversion = 0%.

Figure S2. Maps of FOI projections from LF case/death data and reporting probabilities at the (A) 1st and (B) 2^{nd} administrative levels with seroreversion = 3%.

Figure S3. Scatterplots showing the relationship between the statistical regression predictions of FOI on the x-axis vs. the FOI estimates projected from LF case data and reporting probabilities for each of the eight statistical models (plus a null intercept-only model) included in our analysis. Plots are restricted to FOI estimates that were used in model fitting and do not include data held out for model validation. Results are for the 2nd administrative level and a 6% seroreversion rate.

Figure S4. Scatterplots showing the relationship between the statistical regression predictions of FOI on the x-axis vs. the FOI estimates projected from LF case data and reporting probabilities for each of the eight statistical models (plus a null intercept-only model) included in our analysis. Plots are restricted to FOI estimates that were used in model fitting and do not include data held out for model validation. Results are for the 2nd administrative level and a 6% seroreversion rate.

Figure S5. Scatterplots showing the cross-validation performance of each statistical regression model. Regression predictions of FOI for withheld data are on the x-axis vs. the FOI estimates projected from LF case data and reporting probabilities on the y-axis. Results are for the 1st administrative level and a 6% seroreversion rate.

Figure S6. Scatterplots showing the cross-validation performance of each statistical regression model. Regression predictions of FOI for withheld data are on the x-axis vs. the FOI estimates projected from LF case data and reporting probabilities on the y-axis. Results are for the 2nd administrative level and a 6% seroreversion rate.

Figure S7. Map of ensemble model-based FOI estimates at the (A) 1st and (B) 2nd administrative levels with seroreversion = 0%.

Figure S8. Map of ensemble model-based FOI estimates at the (A) 1st and (B) 2nd administrative levels with seroreversion = 3%.

Figure S9. Map of ensemble model-based FOI estimates at the (A) 1st and (B) 2nd administrative levels with seroreversion = 6%.

References

- 1. Garry RF. Lassa fever the road ahead. *Nat Rev Microbiol*. 2023;21(2):87-96. doi:10.1038/s41579- 022-00789-8
- 2. WHO. Lassa fever. Accessed January 30, 2024. https://www.who.int/health-topics/lassa-fever
- 3. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. A Prospective Study of the Epidemiology and Ecology of Lassa Fever. *The Journal of Infectious Diseases*. 1987;155(3):437-444. doi:10.1093/infdis/155.3.437
- 4. US CDC. Lassa Fever | CDC. April 26, 2022. Accessed January 30, 2024. https://www.cdc.gov/vhf/lassa/index.html
- 5. Redding DW, Gibb R, Dan-Nwafor CC, et al. Geographical drivers and climate-linked dynamics of Lassa fever in Nigeria. *Nat Commun*. 2021;12(1):5759. doi:10.1038/s41467-021-25910-y
- 6. LaVergne SM, Sakabe S, Momoh M, et al. Expansion of CD8+ T cell population in Lassa virus survivors with low T cell precursor frequency reveals durable immune response in most survivors. *PLOS Neglected Tropical Diseases*. 2022;16(11):e0010882. doi:10.1371/journal.pntd.0010882
- 7. Safronetz D, Sogoba N, Diawara SI, et al. Annual Incidence of Lassa Virus Infection in Southern Mali. *Am J Trop Med Hyg*. 2017;96(4):944-946. doi:10.4269/ajtmh.16-0821
- 8. Shaffer JG, Schieffelin JS, Momoh M, et al. Space-Time Trends in Lassa Fever in Sierra Leone by ELISA Serostatus, 2012–2019. *Microorganisms*. 2021;9(3):586. doi:10.3390/microorganisms9030586
- 9. Shaffer JG, Schieffelin JS, Gbakie M, et al. A medical records and data capture and management system for Lassa fever in Sierra Leone: Approach, implementation, and challenges. *PLOS ONE*. 2019;14(3):e0214284. doi:10.1371/journal.pone.0214284
- 10. Sigfrid L, Moore C, Salam AP, et al. A rapid research needs appraisal methodology to identify evidence gaps to inform clinical research priorities in response to outbreaks—results from the Lassa fever pilot. *BMC Medicine*. 2019;17(1):107. doi:10.1186/s12916-019-1338-1
- 11. Siddle KJ, Eromon P, Barnes KG, et al. Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018. *New England Journal of Medicine*. 2018;379(18):1745-1753. doi:10.1056/NEJMoa1804498
- 12. Dalhat MM, Olayinka A, Meremikwu MM, et al. Epidemiological trends of Lassa fever in Nigeria, 2018–2021. *PLOS ONE*. 2022;17(12):e0279467. doi:10.1371/journal.pone.0279467
- 13. Koch MR, Kanneh L, Wise PH, et al. Health seeking behavior after the 2013–16 Ebola epidemic: Lassa fever as a metric of persistent changes in Kenema District, Sierra Leone. *PLOS Neglected Tropical Diseases*. 2021;15(7):e0009576. doi:10.1371/journal.pntd.0009576
- 14. Penfold S, Adegnika AA, Asogun D, et al. A prospective, multi-site, cohort study to estimate incidence of infection and disease due to Lassa fever virus in West African countries (the Enable Lassa research programme)–Study protocol. *PLoS One*. 2023;18(3):e0283643. doi:10.1371/journal.pone.0283643
- 15. Goios A, Varma A, Kagia C, Otiende M, Suykerbuyk P. Enable Lassa Research Programme Mid-term Workshop. Published online 2022. Accessed August 12, 2024. https://media.tghn.org/medialibrary/2023/03/CEPI_Enable_2022_Abuja_Report_Final.pdf
- 16. Lecompte E, Fichet-Calvet E, Daffis S, et al. Mastomys natalensis and Lassa Fever, West Africa. *Emerging Infectious Diseases*. 2006;12(12):1971-1974. doi:10.3201/eid1212.060812
- 17. Fichet-Calvet E, Lecompte E, Koivogui L, et al. Fluctuation of abundance and Lassa virus prevalence in Mastomys natalensis in Guinea, West Africa. *Vector-Borne and Zoonotic Diseases*. 2007;7(2):119- 128.
- 18. Fichet-Calvet E, Becker-Ziaja B, Koivogui L, Günther S. Lassa Serology in Natural Populations of Rodents and Horizontal Transmission. *Vector Borne Zoonotic Dis*. 2014;14(9):665-674. doi:10.1089/vbz.2013.1484
- 19. Clark J, Yakob L, Douno M, et al. Domestic risk factors for increased rodent abundance in a Lassa fever endemic region of rural Upper Guinea. *Sci Rep*. 2021;11(1):20698. doi:10.1038/s41598-021- 00113-z
- 20. Safronetz D, Sogoba N, Lopez JE, et al. Geographic Distribution and Genetic Characterization of Lassa Virus in Sub-Saharan Mali. *PLOS Neglected Tropical Diseases*. 2013;7(12):e2582. doi:10.1371/journal.pntd.0002582
- 21. Mariën J, Lo Iacono G, Rieger T, Magassouba N, Günther S, Fichet-Calvet E. Households as hotspots of Lassa fever? Assessing the spatial distribution of Lassa virus-infected rodents in rural villages of Guinea. *Emerg Microbes Infect*. 2020;9(1):1055-1064. doi:10.1080/22221751.2020.1766381
- 22. Happi AN, Olumade TJ, Ogunsanya OA, et al. Increased Prevalence of Lassa Fever Virus-Positive Rodents and Diversity of Infected Species Found during Human Lassa Fever Epidemics in Nigeria. *Microbiology Spectrum*. 2022;10(4):e00366-22. doi:10.1128/spectrum.00366-22
- 23. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. A Prospective Study of the Epidemiology and Ecology of Lassa Fever. *The Journal of Infectious Diseases*. 1987;155(3):437-444. doi:10.1093/infdis/155.3.437

- 24. Safronetz D, Sogoba N, Diawara SI, et al. Annual Incidence of Lassa Virus Infection in Southern Mali. *Am J Trop Med Hyg*. 2017;96(4):944-946. doi:10.4269/ajtmh.16-0821
- 25. Basinski AJ, Fichet-Calvet E, Sjodin AR, et al. Bridging the gap: Using reservoir ecology and human serosurveys to estimate Lassa virus spillover in West Africa. *PLOS Computational Biology*. 2021;17(3):e1008811. doi:10.1371/journal.pcbi.1008811
- 26. Peterson AT, Moses LM, Bausch DG. Mapping Transmission Risk of Lassa Fever in West Africa: The Importance of Quality Control, Sampling Bias, and Error Weighting. *PLOS ONE*. 2014;9(8):e100711. doi:10.1371/journal.pone.0100711
- 27. Fichet-Calvet. Risk Maps of Lassa Fever in West Africa. *PLOS Neglected Tropical Diseases*. 2009;3(3):e388. doi:10.1371/journal.pntd.0000388
- 28. Redding DW, Moses LM, Cunningham AA, Wood J, Jones KE. Environmental-mechanistic modelling of the impact of global change on human zoonotic disease emergence: a case study of Lassa fever. *Methods in Ecology and Evolution*. 2016;7(6):646-655. doi:10.1111/2041-210X.12549
- 29. Safronetz D, Sogoba N, Lopez JE, et al. Geographic Distribution and Genetic Characterization of Lassa Virus in Sub-Saharan Mali. *PLOS Neglected Tropical Diseases*. 2013;7(12):e2582. doi:10.1371/journal.pntd.0002582
- 30. Lassa fever. WHO. Accessed April 27, 2023. https://www.who.int/health-topics/lassa-fever
- 31. Akhmetzhanov AR, Asai Y, Nishiura H. Quantifying the seasonal drivers of transmission for Lassa fever in Nigeria. *Philos Trans R Soc Lond B Biol Sci*. 2019;374(1775):20180268. doi:10.1098/rstb.2018.0268
- 32. Lassa Fever | CDC. April 26, 2022. Accessed May 4, 2023. https://www.cdc.gov/vhf/lassa/index.html

33. Priority diseases. CEPI. Accessed May 4, 2023. https://cepi.net/research_dev/priority-diseases/

- 34. Hallam HJ, Hallam S, Rodriguez SE, et al. Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. *npj Vaccines*. 2018;3(1):1-12. doi:10.1038/s41541-018-0049-5
- 35. Ramanathan R, Stibitz S, Pratt D, Roberts J. Use of controlled human infection models (CHIMs) to support vaccine development: US regulatory considerations. *Vaccine*. 2019;37(31):4256-4261. doi:10.1016/j.vaccine.2019.06.009
- 36. Disease outbreak Lassa fever Nigeria 1 March 2018. WHO | Regional Office for Africa. March 24, 2023. Accessed March 27, 2023. https://www.afro.who.int/health-topics/lassa-fever/outbreak/1 march-2018-nigeria
- 37. Saleh F, Popoola BO, Arinze C, et al. Adapting public health response through lessons learnt: Nigeria's experience from Lassa fever and COVID-19. *BMJ Global Health*. 2022;7(Suppl 7):e007993. doi:10.1136/bmjgh-2021-007993
- 38. Garry RF. Lassa fever the road ahead. *Nat Rev Microbiol*. 2023;21(2):87-96. doi:10.1038/s41579- 022-00789-8
- 39. Siddle KJ, Eromon P, Barnes KG, et al. Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018. *N Engl J Med*. 2018;379(18):1745-1753. doi:10.1056/NEJMoa1804498
- 40. Kernéis S, Koivogui L, Magassouba N, et al. Prevalence and Risk Factors of Lassa Seropositivity in Inhabitants of the Forest Region of Guinea: A Cross-Sectional Study. *PLOS Neglected Tropical Diseases*. 2009;3(11):e548. doi:10.1371/journal.pntd.0000548
- 41. Klempa B, Koulemou K, Auste B, et al. Seroepidemiological study reveals regional co-occurrence of Lassa- and Hantavirus antibodies in Upper Guinea, West Africa. *Tropical Medicine & International Health*. 2013;18(3):366-371. doi:10.1111/tmi.12045
- 42. Longet S, Leggio C, Bore JA, et al. Influence of Landscape Patterns on Exposure to Lassa Fever Virus, Guinea. *Emerg Infect Dis*. 2023;29(2):304-313. doi:10.3201/eid2902.212525
- 43. Lukashevich IS, Clegg JC, Sidibe K. Lassa virus activity in Guinea: distribution of human antiviral antibody defined using enzyme-linked immunosorbent assay with recombinant antigen. *J Med Virol*. 1993;40(3):210-217. doi:10.1002/jmv.1890400308
- 44. Fraser DW, Campbell CC, Monath TP, Goff PA, Gregg MB. Lassa Fever in the Eastern Province of Sierra Leone, 1970–1972: I. Epidemiologic Studies. *The American Journal of Tropical Medicine and Hygiene*. 1974;23(6):1131-1139. doi:10.4269/ajtmh.1974.23.1131
- 45. O'Hearn AE, Voorhees MA, Fetterer DP, et al. Serosurveillance of viral pathogens circulating in West Africa. *Virol J*. 2016;13:163. doi:10.1186/s12985-016-0621-4
- 46. Grant DS, Engel EJ, Yerkes NR, et al. Seroprevalence of anti-Lassa Virus IgG antibodies in three districts of Sierra Leone: A cross-sectional, population-based study. *PLOS Neglected Tropical Diseases*. 2023;17(2):e0010938. doi:10.1371/journal.pntd.0010938
- 47. Sogoba N, Rosenke K, Adjemian J, et al. Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali. *Emerg Infect Dis*. 2016;22(4):657-663. doi:10.3201/eid2204.151814
- 48. Tobin. Lassa fever in Nigeria: Insights into seroprevalence and risk factors in rural Edo State: A pilot study. Accessed January 31, 2023. https://jmedtropics.org/article.asp?issn=2276- 7096;year=2015;volume=17;issue=2;spage=51;epage=55;aulast=Tobin
- 49. Merson L, Bourner J, Jalloh S, et al. Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design. *PLOS Neglected Tropical Diseases*. 2021;15(9):e0009788. doi:10.1371/journal.pntd.0009788
- 50. Nimo-Paintsil SC, Fichet-Calvet E, Borremans B, et al. Rodent-borne infections in rural Ghanaian farming communities. *PLOS ONE*. 2019;14(4):e0215224. doi:10.1371/journal.pone.0215224
- 51. Fichet-Calvet E, Rogers DJ. Risk Maps of Lassa Fever in West Africa. *PLoS Negl Trop Dis*. 2009;3(3):e388. doi:10.1371/journal.pntd.0000388
- 52. Mylne AQN, Pigott DM, Longbottom J, et al. Mapping the zoonotic niche of Lassa fever in Africa. *Transactions of The Royal Society of Tropical Medicine and Hygiene*. 2015;109(8):483-492. doi:10.1093/trstmh/trv047
- 53. Bangura U. *Molecular Epidemiology of Lassa Virus in the Mano River Union Area, West Africa*. doctoralThesis. Staats- und Universitätsbibliothek Hamburg Carl von Ossietzky; 2022. Accessed January 22, 2023. https://ediss.sub.uni-hamburg.de/handle/ediss/9660
- 54. Demby AH, Inapogui A, Kargbo K, et al. Lassa Fever in Guinea: II. Distribution and Prevalence of Lassa Virus Infection in Small Mammals. *Vector-Borne and Zoonotic Diseases*. 2001;1(4):283-297. doi:10.1089/15303660160025912
- 55. Fichet-Calvet E, Becker-Ziaja B, Koivogui L, Günther S. Lassa Serology in Natural Populations of Rodents and Horizontal Transmission. *Vector-Borne and Zoonotic Diseases*. 2014;14(9):665-674. doi:10.1089/vbz.2013.1484
- 56. Olayemi A, Oyeyiola A, Obadare A, et al. Widespread arenavirus occurrence and seroprevalence in small mammals, Nigeria. *Parasit Vectors*. 2018;11:416. doi:10.1186/s13071-018-2991-5

100

- 57. Mariën J, Lo Iacono G, Rieger T, Magassouba N, Günther S, Fichet-Calvet E. Households as hotspots of Lassa fever? Assessing the spatial distribution of Lassa virus-infected rodents in rural villages of Guinea. *Emerg Microbes Infect*. 2020;9(1):1055-1064. doi:10.1080/22221751.2020.1766381
- 58. Bangura U, Buanie J, Lamin J, et al. Lassa Virus Circulation in Small Mammal Populations in Bo District, Sierra Leone. *Biology (Basel)*. 2021;10(1):28. doi:10.3390/biology10010028
- 59. Agbonlahor DE, Erah A, Agba IM, et al. Prevalence of Lassa virus among rodents trapped in three South-South States of Nigeria. *J Vector Borne Dis*. 2017;54(2):146-150.
- 60. Seroprevalence of anti-Lassa Virus IgG antibodies in three districts of Sierra Leone: A cross-sectional, population-based study | PLOS Neglected Tropical Diseases. Accessed February 21, 2023. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0010938#pntd.0010938.s001
- 61. Lerch A, ten Bosch QA, L'Azou Jackson M, et al. Projecting vaccine demand and impact for emerging zoonotic pathogens. *BMC Med*. 2022;20:202. doi:10.1186/s12916-022-02405-1
- 62. Shaffer JG, Schieffelin JS, Gbakie M, et al. A medical records and data capture and management system for Lassa fever in Sierra Leone: Approach, implementation, and challenges. *PLOS ONE*. 2019;14(3):e0214284. doi:10.1371/journal.pone.0214284
- 63. Worldpop A Census Database. Accessed August 27, 2014. http://www.worldpop.org.uk/data/methods/
- 64. Redding DW, Gibb R, Dan-Nwafor CC, et al. Geographical drivers and climate-linked dynamics of Lassa fever in Nigeria. *Nat Commun*. 2021;12:5759. doi:10.1038/s41467-021-25910-y
- 65. Fichet-Calvet E, Lecompte E, Koivogui L, et al. Fluctuation of Abundance and Lassa Virus Prevalence in *Mastomys natalensis* in Guinea, West Africa. *Vector-Borne and Zoonotic Diseases*. 2007;7(2):119- 128. doi:10.1089/vbz.2006.0520
- 66. Weiss DJ, Nelson A, Gibson HS, et al. A global map of travel time to cities to assess inequalities in accessibility in 2015. *Nature*. 2018;553(7688):333-336. doi:10.1038/nature25181
- 67. Barber RM, Fullman N, Sorensen RJD, et al. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. *The Lancet*. 2017;390(10091):231-266. doi:10.1016/S0140-6736(17)30818-8
- 68. Olson DM, Dinerstein E, Wikramanayake ED, et al. Terrestrial Ecoregions of the World: A New Map of Life on Earth: A new global map of terrestrial ecoregions provides an innovative tool for conserving biodiversity. *BioScience*. 2001;51(11):933-938. doi:10.1641/0006- 3568(2001)051[0933:TEOTWA]2.0.CO;2
- 69. ESA. Land Cover CCI Product User Guide Version 2. Published online 2017. Accessed June 26, 2023. http://maps.elie.ucl.ac.be/CCI/viewer/download/ESACCI-LC-Ph2-PUGv2_2.0.pdf
- 70. Hansen MC, Potapov PV, Moore R, et al. High-resolution global maps of 21st-century forest cover change. *Science*. 2013;342(6160):850-853. doi:10.1126/science.1244693
- 71. Tusting LS, Bisanzio D, Alabaster G, et al. Mapping changes in housing in sub-Saharan Africa from 2000 to 2015. *Nature*. 2019;568(7752):391-394. doi:10.1038/s41586-019-1050-5
- 72. Smits J, Steendijk R. The International Wealth Index (IWI). *Soc Indic Res*. 2015;122(1):65-85. doi:10.1007/s11205-014-0683-x
- 73. Jagadesh S, Zhao C, Mulchandani R, Van Boeckel TP. Mapping Global Bushmeat Activities to Improve Zoonotic Spillover Surveillance by Using Geospatial Modeling. *Emerg Infect Dis*. 2023;29(4):742-750. doi:10.3201/eid2904.221022
- 74. Perkins TA, Huber JH, Tran QM, et al. Burden is in the eye of the beholder: Sensitivity of yellow fever disease burden estimates to modeling assumptions. *Sci Adv*. 2021;7(42):eabg5033.

doi:10.1126/sciadv.abg5033

- 75. Ehichioya DU, Asogun DA, Ehimuan J, et al. Hospital-based surveillance for Lassa fever in Edo State, Nigeria, 2005–2008. *Tropical Medicine & International Health*. 2012;17(8):1001-1004. doi:10.1111/j.1365-3156.2012.03010.x
- 76. Ugwu C, Olumade T, Nwakpakpa E, et al. Humoral and cellular immune responses to Lassa fever virus in Lassa fever survivors and their exposed contacts in Southern Nigeria. *Sci Rep*. 2022;12(1):22330. doi:10.1038/s41598-022-26045-w
- 77. Monath TP, Mertens PE, Patton R, et al. A hospital epidemic of Lassa fever in Zorzor, Liberia, March-April 1972. *The American Journal of Tropical Medicine and Hygiene*. 1973;22(6):773-779. doi:10.4269/ajtmh.1973.22.773
- 78. Fisher-Hoch SP, Tomori O, Nasidi A, et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. *BMJ*. 1995;311(7009):857-859. doi:10.1136/bmj.311.7009.857
- 79. Dan-Nwafor CC, Ipadeola O, Smout E, et al. A cluster of nosocomial Lassa fever cases in a tertiary health facility in Nigeria: description and lessons learned, 2018. *International Journal of Infectious Diseases*. Published online March 28, 2019. doi:10.1016/j.ijid.2019.03.030

- 80. Sogoba N, Feldmann H, Safronetz D. Lassa Fever in West Africa: Evidence for an Expanded Region of Endemicity. *Zoonoses and Public Health*. 2012;59(s2):43-47. doi:10.1111/j.1863-2378.2012.01469.x
- 81. Sogoba N, Rosenke K, Adjemian J, et al. Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali. *Emerg Infect Dis*. 2016;22(4):657-663. doi:10.3201/eid2204.151814
- 82. Lindgren F, Rue H, Lindström J. An explicit link between Gaussian fields and Gaussian Markov random fields: the stochastic partial differential equation approach. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*. 2011;73(4):423-498. doi:10.1111/j.1467- 9868.2011.00777.x
- 83. Bhatt S, Cameron E, Flaxman SR, Weiss DJ, Smith DL, Gething PW. Improved prediction accuracy for disease risk mapping using Gaussian process stacked generalization. *Journal of The Royal Society Interface*. 2017;14(134):20170520. doi:10.1098/rsif.2017.0520
- 84. Barua S, Dénes A, Ibrahim MA. A seasonal model to assess intervention strategies for preventing periodic recurrence of Lassa fever. *Heliyon*. 2021;7(8):e07760. doi:10.1016/j.heliyon.2021.e07760
- 85. Leski TA, Stockelman MG, Moses LM, et al. Sequence Variability and Geographic Distribution of Lassa Virus, Sierra Leone. *Emerg Infect Dis*. 2015;21(4):609-618. doi:10.3201/eid2104.141469
- 86. Happi AN, Olumade TJ, Ogunsanya OA, et al. Increased Prevalence of Lassa Fever Virus-Positive Rodents and Diversity of Infected Species Found during Human Lassa Fever Epidemics in Nigeria. Anderson MZ, ed. *Microbiol Spectr*. 2022;10(4):e00366-22. doi:10.1128/spectrum.00366-22
- 87. Klitting R, Kafetzopoulou LE, Thiery W, et al. Predicting the evolution of the Lassa virus endemic area and population at risk over the next decades. *Nat Commun*. 2022;13:5596. doi:10.1038/s41467-022- 33112-3

- 88. Omilabu SA, Badaru SO, Okokhere P, et al. Lassa Fever, Nigeria, 2003 and 2004. *Emerg Infect Dis*. 2005;11(10):1642-1644. doi:10.3201/eid1110.041343
- 89. Dan-Nwafor CC, Ipadeola O, Smout E, et al. A cluster of nosocomial Lassa fever cases in a tertiary health facility in Nigeria: Description and lessons learned, 2018. *International Journal of Infectious Diseases*. 2019;83:88-94. doi:10.1016/j.ijid.2019.03.030
- 90. Shaibu JO, Salu OB, Amoo OS, et al. Immunological screening of Lassa Virus among Health workers and Contacts of patients of Lassa fever in Ondo State. *Immunobiology*. 2021;226(3):152076. doi:10.1016/j.imbio.2021.152076
- 91. Fick SE, Hijmans RJ. WorldClim 2: new 1-km spatial resolution climate surfaces for global land areas. *International Journal of Climatology*. 2017;37(12):4302-4315. doi:10.1002/joc.5086
- 92. Didan K. Mod13a3 modis/terra vegetation indices monthly l3 global 1km sin grid v006. *NASA EOSDIS Land Processes DAAC*. 2015;10.
- 93. Abrams M, Crippen R, Fujisada H. ASTER Global Digital Elevation Model (GDEM) and ASTER Global Water Body Dataset (ASTWBD). *Remote Sensing*. 2020;12(7):1156. doi:10.3390/rs12071156
- 94. Schneider A, Friedl MA, Potere D. A new map of global urban extent from MODIS satellite data. *Environ Res Lett*. 2009;4(4):044003. doi:10.1088/1748-9326/4/4/044003
- 95. Nachtergaele F, Petri M. *Mapping Land Use Systems at Global and Regional Scales for Land Degradation Assessment Analysis Freddy Nachtergaele*. Land Degradation Assessment in Drylands; 2008. Accessed March 21, 2023. https://www.researchgate.net/profile/F-Nachtergaele/publication/265754296 Mapping Land Use Systems at global and regional scales _for_Land_Degradation_Assessment_Analysis_Version_10/links/5437eebb0cf2027cbb205c28/Map

ping-Land-Use-Systems-at-global-and-regional-scales-for-Land-Degradation-Assessment-Analysis-

Version-10.pdf

96. Weiss DJ, Lucas TCD, Nguyen M, et al. Mapping the global prevalence, incidence, and mortality of

Plasmodium falciparum, 2000–17: a spatial and temporal modelling study. *The Lancet*.

2019;394(10195):322-331. doi:10.1016/S0140-6736(19)31097-9